Acadia Pharmaceuticals (ACAD) - attractive low-risk biotech investment opportunity

My price target for ACAD is now $39-$57 per share which presents over 150% upside potential.

I used the Times Revenue Multiple Valuation method.
Below is my Valuation Model with assumptions:

I wrote about ACAD and it drug candidate back in April 2015.

I continue to view ACAD as an excellent low-risk investment opportunity.



Disclosure - ACAD is a core holding of my Marketocracy Fund. This Fund is available for investment.
I do not short stocks.